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Abstract 
Background: Magnetic resonance imaging (MRI) is indispensable for diagnosing neurological conditions such 
as multiple sclerosis (MS). MRI also supports decisions regarding the choice of disease-modifying drugs 
(DMDs). Determining in vivo tissue concentrations of DMDs has the potential to become an essential clinical 
tool for therapeutic drug monitoring (TDM). The aim here was to examine the feasibility of fluorine-19 (19F) 
MR methods to detect the fluorinated DMD teriflunomide (TF) during normal and pathological conditions. 
Methods: We used 19F MR spectroscopy to detect TF in the experimental autoimmune encephalomyelitis 
(EAE) mouse model of multiple sclerosis (MS) in vivo. Prior to the in vivo investigations we characterized the MR 
properties of TF in vitro. We studied the impact of pH and protein binding as well as MR contrast agents. 
Results: We could detect TF in vivo and could follow the 19F MR signal over different time points of disease. 
We quantified TF concentrations in different tissues using HPLC/MS and showed a significant correlation 
between ex vivo TF levels in serum and the ex vivo 19F MR signal. 
Conclusion: This study demonstrates the feasibility of 19F MR methods to detect TF during neuro-
inflammation in vivo. It also highlights the need for further technological developments in this field. The ultimate 
goal is to add 19F MR protocols to conventional 1H MRI protocols in clinical practice to guide therapy decisions. 
Key words: MRI, MRS, Fluorine, Teriflunomide, Magnetic Resonance Spectroscopy, experimental autoimmune 
encephalomyelitis, Multiple Sclerosis 
Introduction 
Multiple sclerosis (MS) is a chronic inflammatory 
disease of the central nervous system (CNS) [1, 2]. The 
disease course is highly variable, involving a wide 
spectrum of neurological and motoric symptoms [3]. 
Most patients show a relapsing and remitting (RRMS) 
disease course, which ultimately transitions to a 
progressive phase [2, 4]. 
1H Magnetic resonance imaging (1H MRI) has 
been indispensable for diagnosing MS [5-7]. 1H MRI 
can distinguish chronic from active lesions when 
using contrast agents to reveal blood brain barrier 









vital for making safe informed decisions with respect 
to disease modifying drugs (DMDs) [12, 13] to ensure 
a better dampening of disease activity [14]. Typically, 
T2 lesion load [15, 16] and brain atrophy [16] are used 
as outcome measures, especially during clinical 
studies. These MRI endpoints are commonly used as 
primary and secondary measures in phase II DMD 
trials involving large amounts of patients [17]. Despite 
the substantial armamentarium of DMDs available for 
MS [18-20], predicting treatment outcomes and 
tailoring DMD dosages to treatment objectives for 
individual patients poses a major unmet clinical need 
[21-23]. DMDs may need to traverse the BBB, to 
modify inflammatory responses within the CNS or to 
reduce neurodegeneration [24]. 
Currently there are no standard clinical methods 
to non-invasively monitor the distribution of drugs in 
patients. However, the possibility to quantify the 
concentration of drugs in the brain would greatly 
improve the assessment of individual treatment 
responses [22]. Drug levels are typically measured in 
blood, urine, saliva, and infrequently cerebrospinal 
fluid (CSF). However, drug levels in these fluids do 
not reliably reflect concentrations within the CNS. 
Imaging techniques such as positron emission 
tomography (PET) and single-photon emission 
computed tomography (SPECT) are used to detect 
drugs labeled with a radioisotope; these imaging 
methods are highly sensitive and are particularly 
useful in phase I clinical studies for small cohorts of 
human subjects [25-29]. However, they are not used 
for standard drug monitoring in patients; 
disadvantages include high costs, the necessity to 
inject radioactive compounds, restricted observation 
window due to short radiotracer half-life (18F t1/2 = 
110 min), and a lack of distinction between drugs and 
their metabolites. 
One third of all approved drugs are fluorinated, 
and are potentially detectable by fluorine-19 (19F) MRI 
in vivo [30-32]. The amount of 19F atoms endogenously 
present in the human body that can be detected with 
MR methods is negligible. The absence of background 
signal makes the 19F nucleus a unique and highly 
attractive biomarker for detecting administered 
fluorinated DMDs in vivo using 19F-MR methods. 19F 
MR methods have been applied to detect fluorinated 
drugs in animal [33-38] and human studies [39-45] in 
the past. They have also been applied in combination 
with drugs encapsulated in fluorine rich nanoparticles 
to monitor the efficacy of these therapies in animal 
models [46]. 19F-MR methods have also been 
employed in diagnostic imaging [47], for guiding 
tumor ablation therapies [48], and for imaging 
intracellular therapeutic targeting [49]. However, they 
remain under-utilized for the majority of drugs, 
especially in MS. 
Teriflunomide (TF) is an anti-inflammatory 
DMD approved for use in MS that contains a 
trifluoromethyl group [50]. TF is administered orally 
once-daily and has a rapid, complete absorption with 
a long half-life (> 2 weeks) due to extensive 
enterohepatic recycling [51]. In RRMS patients, it 
reduces the annual relapse rate, slows disability 
progression, reduces the lesion volume [51, 52] and 
brain volume loss [53]. TF has a high tolerability and 
low discontinuation rate [50, 54]. TF was investigated 
in preclinical studies using the animal model of MS, 
experimental autoimmune encephalomyelitis (EAE) 
[55-57]. In rats, TF administration at EAE onset 
reduced disease severity and delayed progression [55, 
57]. TF treatment delayed EAE onset in SJL/J mice, 
and suppressed disease entirely in C57BL/6 mice.  
In this study we used 19F MR spectroscopy to 
study the possibility of detecting TF during EAE in 
vivo. We characterized the MR properties of TF in 
vitro, studying the impact of pH, protein binding, and 
MR contrast agents. We demonstrated the feasibility 
of 19F MR methods to detect TF non-invasively during 
neuroinflammation, with the ultimate goal for further 
development into future clinical applications. 
Methods 
Teriflunomide 
Teriflunomide (TF) (Sanofi-Genzyme, 
Bridgewater, US) was formulated in 0.6% 
carboxymethylcellulose, sodium salt (CMC, Sigma, 
Schnelldorf, Germany) in the form of a suspension for 
in vivo use. CMC is an inactive ingredient used as 
thickening excipient, stabilizer and suspending agent. 
TF (20 mg) was mixed with 5 mL CMC/Tween-80 
(0.6% CMC, 0.5% Tween-80 in water) using medium 
speed magnetic stirring (circa 24 h at RT) until a 
uniform milky suspension was obtained. The 
suspension was transferred to a clean glass vial and 
the original vial rinsed with a further 5 mL of 
CMC/Tween-80. The TF suspension (2 mg/mL) was 
adjusted to a pH of 7 using HCl and NaOH. For 
phantom experiments, TF was prepared in CMC, 
DMSO and human serum to study the effects of 
protein binding. 
Animals 
Dark Agouti rats (n = 2, Janvier Labs, Le 
Genest-Saint-Isle, France), C57BL/6N mice (n = 27, 
Charles River, Sulzfeld, Germany) and SJL/J (n = 33, 
Janvier Labs, Le Genest-Saint-Isle, France) mice (all 
female, age 2-4 months) were used to study the TF 
signal following oral application in vivo. The numbers 
of animals within each group are specified in the 
relevant experiments below. 





Animal experiments were conducted in 
accordance with procedures approved by the Animal 
Welfare Department of the State Office of Health and 
Social Affairs Berlin (LAGeSo) and conformed to 
guidelines to minimize discomfort to animals 
(86/609/EEC). 
EAE induction 
EAE was induced by subcutaneous 
immunization of SJL/J mice with proteolipid protein 
peptide (PLP139–151) and C57BL/6 mice with myelin 
oligodendrocyte glycoprotein peptide (MOG35-55); for 
both peptides 250 µg peptide (Pepceuticals, Leicester, 
UK) per animal were emulsified with M. Tuberculosis 
H37RA (List Biological Laboratories, Campbell, US, 
800 µg/animal) in 100 µL Complete Freund's 
Adjuvant (BD Difco, Heidelberg, Germany). Pertussis 
Toxin (Biotrend, Cologne, Germany, 1.25 ng/µL in 
SJL/J and 2 ng/µL in C57BL/6) was administered 
intraperitoneally in 200 µL PBS on days 0 and 2 [58]. 
EAE scoring was performed daily: righting 
reflex weakness = 0.5, tail paresis = 0.5, tail paralysis = 
1, unilateral hindlimb paresis = 0.5, bilateral hindlimb 
paralysis = 1, unilateral forelimb paresis = 0.75, 
bilateral forelimb paralysis = 1.5. 
Teriflunomide treatment and preparation for 
in vivo MR measurements 
Rats (n = 2) were treated orally with 10 mg/kg 
TF and MR measurements were performed directly 
following administration. Animals were anesthetized 
by intraperitoneal (ip) injection using ketamine 
(40 mg/kg, WDT, Garbsen, Germany) and 
medetomidine (0.5 to 0.75 mg/kg, Henry Schein, 
Berlin, Germany) maintained by an ip catheter line. 
TF was administered via a catheter line to the stomach 
while the animal was in the scanner. 
Mice were treated daily for 14 days with 
30 mg/kg TF [55-57, 59] or vehicle control (CMC) 
administered by oral gavage. The increased dose used 
in mice takes into consideration guidelines on dose 
conversions in animals and is mostly due to 
differences in metabolism [56, 60]. EAE mice were 
treated with TF (C57BL/6 n = 12, SJL/J n = 12) or 
CMC (C57BL/6 n = 6, SJL/J n = 6). Healthy 
non-immunized C57BL/6 (n = 9) or SJL/J (n = 15) 
mice served as therapy controls. MR measurements in 
mice were performed on days 8 and 14 following EAE 
start, 16-24 h after the last drug administration. For in 
vivo MR measurements, mice were anesthetized by 
intraperitoneal injection using a mixture of xylazine 
(5 mg/kg, CP Pharma, Burgdorf, Germany) and 
ketamine (50 mg/kg, WDT, Garbsen, Germany) 
maintained by an ip catheter line. 
Animals were transferred to a temperature- 
regulated bed (receiving circulated warm water from 
a water bath) and supplied with pressurized air (30 %) 
and O2 (70 %). Pulse, respiration and body 
temperature (Neoptix, OmniLink version 1.15, 
Omniflex, Neoptix, Québec, Canada) were 
continuously monitored. The body temperature was 
kept at 37 °C throughout the experiments. 
For studying the BBB disruption in SJL/J EAE 
mice, gadopentetate dimeglumine (0.2 mmol/kg Gd- 
DTPA Magnevist, Bayer Pharma, Berlin, Germany) 
was administered intravenously via the tail vein using 
an infusion pump (Harvard PHD 2000, Harvard 
Apparatus, Cambridge, US). 
Phantom construction 
For characterizing the 19F MR properties 
(chemical shift, spectral shape and relaxation times) of 
TF, phantoms were prepared in 2.5 mL syringes (inner 
diameter, id: 9.7 mm, total length: 7.6 cm, B.Braun, 
Melsungen, Germany) equipped with stopper 
closing-cones (B.Braun, Melsungen, Germany) using 
dimethylsulfoxide (DMSO, Roth, Karlsruhe, 
Germany, 27.02 mg/mL), human serum 
(4.84 mg/mL) or CMC (2.70 mg/mL) as solvents/ 
suspending agent. Given the different pH of various 
compartments in vivo, we studied the influence of pH 
on the relaxation times T1 and T2 as well as the 19F 
signal intensity in CMC in 1 mL syringes (id: 4.7 mm, 
total length: 9.6 cm, B.Braun, Melsungen, Germany). 
The pH for the 2.70 mg/mL TF concentration was 
adjusted to pH values of 5, 7.4, 10 and 13 with HCl or 
NaOH. 
For studying the influence of contrast agent on 
19F MR properties, 4 phantoms containing 16.67 
mg/mL TF and different concentrations of Gd-DTPA 
(0.5 mM, 1 mM, 2 mM, and 4 mM) in DMSO were 
prepared in NMR tubes (id: 4.2 mm). 
For assessing the limit of detection (LOD) for 19F 
MRS and performing calibrations, four TF 
concentrations were prepared in serum (400 µL) and 
the exact concentration for each sample was 
determined by mass spectrometry (11.8, 105.7, 787.4, 
4208.2 µg/g). The serum samples (350 to 500 µL) were 
prepared in 1 mL syringes (as above). 
MR methods 
Hardware 
MR experiments were performed on a Bruker 
Biospec 9.4 T MR scanner (Bruker Biospin, Ettlingen, 
Germany) with a horizontal bore. A room 
temperature (RT) dual-tunable 19F/1H head RF 
transceive coil (16 mm inner diameter) [61] was used 
to characterize TF in DMSO/serum/CMC in phantom 
experiments. 
A RT dual-tunable 19F/1H rat body RF transceive 





coil (MRI.TOOLS GmbH, Berlin, Germany, 62 mm 
inner diameter) was used to study in vivo 19F MR 
spectroscopy (MRS) signals in the abdomen of the rat.  
A cryogenically-cooled transceive 19F quadrature 
RF surface probe (20 mm inner diameter, Cryogenic 
Radiofrequency Probe, CRP, Bruker, Fällanden, 
Switzerland) [62] was used for in vivo 19F MRS 
measurements of the mouse head and abdomen as 
well as serum samples. With this coil we had 
previously shown that 19F MR sensitivity is enhanced 
by a factor of 15 compared to RT head coils [62]. The 
bed of the 19F CRP was adjusted with respect to the 
surface of the coil in order to acquire 19F MRS in 
different regions of the mouse body. The 
measurement volume above the bed was adjusted 
with respect to the surface of the coil-head by using a 
position gauge. This device reproduces the geometry 
of the coil-head and supporting components and can 
be used to adjust the position of the mouse on the bed 
outside of the MR scanner. Anatomical 1H scans 
ensured correct positioning and complete coverage of 
the regions of interest. 
Phantom MR measurements 
A non-selective single-pulse 19F MRS FID- 
acquire sequence (TR = 1000 ms, nominal flip angle = 
90°, blockpulse, 4096 sampling points, acquisition 
delay = 0.05 ms, excitation pulse bandwidth = 10000 
Hz, spectral read bandwidth = 25000 Hz, averages for 
serum/CMC/DMSO phantoms: avgserum = 8, 
avgCMC = 16, avgDMSO = 16) was used for detecting TF 
in phantoms and studying chemical shift and spectral 
shape (full-width half maximum, FWHM). This 
sequence (later referred to as default) was slightly 
modified e.g. using increased averages or bandwidth 
to increase signal-to-noise ratio (SNR) in in vivo and ex 
vivo experiments (see below). 
19F T1 and T2 relaxation times were measured 
using MR spectroscopy. For T1, the default FID- 
acquire sequence was used but with 16 TRs ranging 
from 100 to 10000 ms, avgserum = 40, avgDMSO = 30, 
avgCMC = 30. For T2, a CPMG pulse sequence was 
used: 25 echoes, echo spacing for serum/CMC/ 
DMSO phantoms: esserum = 2.8 ms, esDMSO = 40 ms, 
esDMSO+Gd-DTPA = 10.6 ms, esCMC = 10.6 ms, excitation 
pulse = 5000 Hz, spectral read bandwidth = 25000 Hz; 
TRserum = 2000 ms, TRDMSO = 5000 ms, TRCMC = 5000 
ms, avg = 50 (for all phantoms). 
For studying the influence of pH on the 19F MR 
signal detection, the default FID-acquire sequence 
was used, but a long TR of 8000 ms was chosen to 
allow full relaxation. 
The LOD for the 19F CRP to perform 19F MRS in 
vivo was assessed using the above four concentrations 
of TF in serum and the default 19F MRS FID-acquire 
sequence but using avg = 1024, acquisition time = 17 
min. The SNR of these spectra was measured and the 
LOD was determined as the concentration/number of 
19F atoms that corresponded to an SNR of 5 (SNR1 
estimation below) using a linear fit with y-axis 
intercept = 0. The SNR value of 5 was chosen as a 
conservative threshold for determining LOD. 
In vivo 1H MRI using 19F/1H coils 
Anatomical 1H MRI was performed using 
FLASH (Fast Low-Angle Shot) [63] and T2 weighted 
TurboRARE (Rapid Acquisition with Relaxation 
Enhancement) [64] pulse sequences. In EAE mice, BBB 
disruptions were assessed using an MDEFT (Modified 
Driven-Equilibrium FT) [65] sequence with inversion 
(TR/TE/TI 2600/3.9/950 ms, FOV (30.2×12.8×9) 
mm3, matrix size = 256×170×18, avg = 2, acquisition 
time = 3 m 7 s). 
In vivo 19F MRS using 19F CRP 
TF-derived 19F MR signal was studied in healthy 
and EAE mice immediately following acquisition of 
the anatomical scans. To account for the B1 
inhomogeneity of the CRP surface coil during in vivo 
measurements, we calibrated the flip angle. Before in 
vivo measurements, a phantom reference sample of 
1 mL TF in DMSO (27.02 mg/mL) was used to 
manually calibrate the flip angle and reference power. 
This sample was in a 2.5 mL syringe and was 
positioned at the coil surface. We acquired 10 spectra 
with the default 19F MRS FID-acquire sequence using 
different reference powers (0.0001 - 0.01 W). The best 
reference power from these manual measurements 
was verified by the automatically adjusted power 
settings for this sample by the MR system. Prior to 
each in vivo measurement, we adjusted the reference 
power manually (automatic 19F adjustments were not 
possible due to low SNR): spectra (avg = 128, 2 min 
8 s each) with different reference powers (0.001, 0.002, 
0.004, 0.008 W) were acquired from the head region of 
mice in vivo using the default FID-acquire method. 
The optimal reference power yielding the highest 
signal intensity was then chosen for the 19F MRS data 
acquisitions. For these acquisitions, the default 
FID-acquire sequence was used with avg = 1024, 
acquisition time = 17 min. 
In vivo 19F MRS using 19F/1H rat body coil 
To study 19F MRS signal of TF in the abdominal 
region of rats at different time points, the default 
FID-acquire sequence was used with alterations in: 
TR = 1500 ms, avg = 256, acquisition time = 6 min. 





Ex vivo measurements 
Tissue processing 
Animals were sacrificed after 14 days of in vivo 
experiments. Under deep anesthesia, blood was 
withdrawn and animals were transcardially perfused 
with 30 mL (> 10× the estimated total mouse blood 
volume) phosphate-buffered saline (PBS) solution. 
CSF was collected from the cisterna magna and the 
perfused brain was isolated. The perfused brain 
samples are mostly depleted of blood and CSF. 
Samples were frozen (-80 °C) for subsequent mass 
spectrometry studies. 
Perfused brain tissue (50 mg), serum (50 µL) or 
CSF (1-3 mg) was weighed/measured and 
homogenized in 450 µL phosphate buffer 
(100 mmol/L, pH = 6.0). 1 mL ethylacetate was 
added. The mixture was shaken vigorously for 5 min 
and centrifuged at 11000 rpm for 10 min. The upper 
layer was transferred to a 2 mL glass vial. The 
extraction was repeated twice. The organic extract 
was evaporated to dryness with a gentle N2 stream at 
40 °C, after which the residue was dissolved in 1 mL 
ethanol. 
High performance liquid chromatography mass 
spectrometry (HPLC/MS) 
For assessing the LOD for HPLC/MS, 5 TF 
concentrations (1 ng/mL to 1000 ng/mL) were 
prepared in DMSO. LOD was calculated at an SNR = 
9 using peak-to-peak algorithm from lowest calibrator 
1 ng/mL. 
HPLC-measurements were performed using an 
Agilent 1290 HPLC system with binary pump, 
autosampler and column thermostat equipped with a 
Phenomenex Kinetex-C18 column 2.6 µm, 
2.1×150 mm column (Phenomenex, Aschaffenburg, 
Germany). Ammonium acetate (5 mM) and 
acetonitrile was used as solvent system. All solvents 
and buffers in HPLC-MS-grade were obtained from 
VWR Germany. The solvent gradient started at 5 % 
acetonitrile and was increased to 95 % within 5 min 
until 8 min with a flow rate of 0.4 mL/min and 1 µL 
injection volume. The HPLC was coupled with an 
Agilent 6470 triplequad mass spectrometer with 
electrospray ionization source using established 
parameters (gas temp = 250 °C, gas flow = 9 L/min, 
nebulizer pressure = 20 psi, sheath gas temp = 390 °C, 
sheath gas flow = 12 L/min, capillary voltage = 2700 
V, nozzel voltage = 300 V) operated in negative 
multiple reaction monitoring mode (269.2 –160 
capillary electrophoresis (CE) 28 V, – 82 CE 21, 
fragmentor voltage = 120 V, mass resolution 
wide/wide). 
Ex vivo 19F MRS 
For correlating the TF-derived 19F MR signal 
with HPLC/MS TF quantification, calibrations were 
first performed with mouse sera spiked with TF 
(using 3 concentrations closer to biologically expected 
values) in 1 mL syringes. These concentrations were 
measured with HPLC/MS (11.8, 105.7, 787.4 µg/g) 
and the default 19F MRS FID-acquire method (but 
excitation pulse = 70000 Hz, spectral read bandwidth 
= 70000 Hz, avg = 4096, acquisition time = 1 h 8 min). 
Next we measured the ex vivo serum samples from 
EAE mice (n = 10) in 1 mL syringes using the default 
FID-acquire method and HPLC/MS. 
For both the calibration experiment (spiked 
serum) as well as the between-method correlation (ex 
vivo serum) we computed a linear fit with y-axis 
intercept = 0 to determine the relation of signal to 
concentration and then used this ratio to estimate TF 
concentrations in ex vivo serum samples from the 19F 
MRS signal intensity after accounting for slight 
volume differences. 
MR data analysis 
For in vivo proton image processing and analysis, 
the freely available software Fiji (Image J v1.47p, 
Open source software, NIH, MD, USA) [66] was used. 
All spectral analyses and processing were 
performed in MATLAB (The MathWorks Inc., Natick, 
USA). Chemical shifts are referenced to trichloro- 
fluoro-methane, CFCl3 (δF=0 ppm). Post-processing of 
the real spectra included zero-filling to 214 points of all 
original FID data and a line-broadening of 70 Hz. The 
signal from both receive channels was averaged after 
zeroth and first order phase-correction. 
We used two conventions to measure SNR of the 
main spectral peaks: SNR1 was measured by 
calculating the ratio of the peak amplitude (maximal 
peak height minus mean background signal) and one 
standard deviation of the background noise (σ1), as 
suggested in a recent expert’s consensus paper on in 
vivo MR spectroscopy [67]. SNR2 was measured by 
calculating the ratio of the peak amplitude and the 
noise height (peak-to-peak) divided by 2.5 (σ2) [68]. 
Both SNR estimations are shown for all in vivo 19F MR 
measurements in healthy and EAE mice (Table S1). 
SNR1 was used for all data analysis. SNR2 is only 
reported in Table S1. 
The time domain (TD) signal intensity was 
measured by calculating the y-axis intercept of the 
magnitude free-induction decay using a 4–th degree 
polynomial fit (FID fit) in MATLAB. The frequency 
domain (FD) signal intensity was determined by 
computing the integral of the MRS peak at -61 ppm 
(peak area). For this, we used a Lorentzian fit of the 
real spectrum [69] including a baseline offset and a 





secondary peak if the amplitude of the secondary 
peak exceeded SNR1 = 2. Only the area of the main 
peak was attributed to TF. 
T1 and T2 were determined by mono exponential 
fitting of data points obtained from 19F MRS (T1) and 
CPMG (T2, three parameter fit). 
Statistical analysis 
MR-data and mass spectrometry data were 
pooled from all experiments. 19F signal intensities 
from 19F MR and TF concentrations in serum, 
perfused brain tissue and CSF samples from HPLC/ 
MS experiments were log transformed, and the log- 
normal distribution confirmed using the Shapiro-Wilk 
normality test. EAE disease scores were presented as 
mean and standard error of the mean, maximum 
scores as median and interquartile range and were 
analyzed with the Mann-Whitney U test. Bodyweight 
was analyzed using the t-test; the logrank test was 
used to analyze the time-to-onset of clinical signs. 19F 
MR signal detection over time and mass spectrometry 
data was analyzed using ANOVA or 2-factor 
ANOVA, with the Tukey post-hoc test for multiple 
comparisons, or with an unpaired t-test. Levene’s test 
was used for testing for homogeneity of variance. 
Correlation was assessed using the Pearson 
correlation (R) or the non-parametric Spearman 
rank-order correlation (ρ), as appropriate. p-values 
< 5 % were considered significant (depicted as 
*p < 0.05; **p < 0.01; ***p < 0.001). Statistical analysis 
was performed using the statistical computing 
environment R (version 3.6.1, R Foundation; 
https://R-project.org). 
Results 
Strain differences in response to teriflunomide 
treatment in EAE mice 
We studied TF treatment response in both SJL/J 
(Figure 1A-D) and C57BL/6 (Figure 1E-H) EAE mice. 
In SJL/J mice, TF treatment prevented weight loss 
during the EAE disease course (Figure 1A, n = 12, 
 
 
Figure 1. Effect of teriflunomide treatment on the disease course of EAE in SJL/J and C57BL/6 mice. (A) Change in bodyweight (Mean ± SE) over time in untreated 
(carboxymethylcellulose vehicle, n = 5) and TF treated (n = 12) SJL/J EAE mice. Changes in percent compared to the initial bodyweight are shown. (B) Mean EAE score ± SE of 
untreated (n = 5) and TF treated (n = 12) SJL/J EAE animals. The time axis is restricted to days with non-zero EAE score. (C) Maximum EAE score reached during the EAE disease 
course in untreated (n = 5) and TF treated (n = 12) SJL/J EAE animals. (D) Kaplan-Meier plot of untreated (n = 5) and TF treated (n = 12) SJL/J EAE animals depicting the time 
to disease onset (score=0.5) and the proportion of animals with clinical symptoms. (E) Change in bodyweight (Mean ± SE) over time in untreated (carboxymethylcellulose, 
n = 6) and TF treated (n = 9) C57BL/6 EAE mice. Changes in percent of the initial bodyweight is shown. (F) Mean EAE score ± SE of untreated (n = 6) and TF treated (n = 9) 
C57BL/6 EAE animals. The time axis is restricted to days with non-zero EAE score. (G) Maximum EAE score reached during the EAE disease course in untreated (n = 6) and 
treated (n = 9) C57BL/6 EAE animals. (H) Kaplan-Meier plot of untreated (n = 6) and treated (n = 9) C57BL/6 EAE animals depicting the time to onset (score = 0.5) of the EAE 
disease and the proportion of animals with clinical symptoms. (I-J) MR Images showing mild (I) and severe (J) blood brain barrier disruption using contrast agent (i.v.) and MDEFT 
on day 14 in two TF treated EAE mice. Lesions are indicated (yellow arrows) in the cerebellum and also in periventricular regions. Differences in body weight were analysed using 
Student’s t-test; EAE scores and max scores were analysed using the Mann-Whitney U test; time to disease onset was analysed using the logrank test. 





pooled from 4 EAE experiments). Control EAE mice 
(n = 5, pooled from 4 EAE experiments) treated with 
vehicle showed a substantial weight loss from day 11 
post-immunization (p.i.) onward (p = 0.002) (Figure 
1A). TF treatment resulted in an almost complete 
absence of clinical signs in SJL/J mice. TF-treated EAE 
mice had lower clinical scores compared to vehicle- 
treated EAE mice, which showed a typical disease 
course for SJL/J mice, reaching peak clinical score at 
day 12 p.i. (Figure 1B). In the TF-treated group, only 
8% of animals showed clinical signs by day 14 p.i. 
compared to untreated mice (100% incidence). The 
maximum disease score was also different between 
treated (0 ± 0, median ± interquartile range, IQR) and 
untreated (2.5 ± 0.5, median ± IQR) EAE mice 
(p < 0.001) (Figure 1C). TF delayed disease onset 
(p < 0.001), which is defined as time to reach a 
minimum clinical score of 0.5 (Figure 1D). 
The response of C57BL/6 EAE mice (n = 9, 
pooled from 3 EAE experiments) to TF treatment was 
less pronounced. TF-treated C57BL/6 EAE mice 
showed a less marked reduction in weight over time, 
but there was no significant difference in weight loss 
compared to vehicle-treated C57BL/6 EAE controls 
(n = 6, pooled from 3 EAE experiments) (p > 0.1) 
(Figure 1E). TF-treated C57BL/6 mice began to show 
clinical signs by day 10 p.i., and while EAE scores 
were generally lower than those of vehicle treated 
controls, there were no differences in EAE scores 
between the two groups (p > 0.5) (Figure 1F). Also, 
there was no significant decrease in maximum EAE 
score in TF-treated C57BL/6 EAE mice (0.5 ± 2, 
median ± IQR) compared to vehicle-treated (2 ± 1.625, 
median ± IQR) C57BL/6 EAE mice (p > 0.05) (Figure 
1G). TF treatment reduced disease incidence by 65% 
and also delayed onset, compared to untreated mice 
(p = 0.04) (Figure 1H). 
The extent of CNS inflammation was examined 
on day 14 by measuring BBB disruption using 
contrast-enhanced MRI (Figure 1I-J). We observed 
contrast-enhancing lesions in SJL/J EAE mice treated 
with TF, even in the absence of clinical signs. The 
extent of these lesions varied among animals, with 
some showing comparatively mild (Figure 1I) and 
others comparatively severe (Figure 1J) disruption. 
Contrast-enhancing lesions were particularly 
prominent in the cerebellum (Figure 1I-J) and were 
also present in periventricular regions (Figure 1J). 
Environmental factors alter the magnetic 
resonance properties of teriflunomide 
The physicochemical properties of TF in DMSO, 
including chemical shift, 19F T1 and 19F T2 relaxation 
times are shown in Figure 2A-C. Changes in T1 and T2 
occur with different concentrations of gadopentetate 
dimeglumine (Figure 2D). We observed a linear 
correlation between the inverse T1 (R1) (T1-relaxation 
times 1099 ms, 209 ms, 117 ms, 60 ms, 33 ms; Pearson 
R = 0.999, p < 0.001) and inverse of T2 (R2; 
T2-relaxation times 547 ms, 76 ms, 43 ms, 24 ms; 
Pearson R = 0.999, p = 0.001) with increasing 
Gd-DTPA concentrations (Figure 2D). 
TF in CMC exhibits a single narrow peak 
spectrum (FWHM = 116 Hz) at -61 ppm (Figure 2E), 
in comparison to a peak at -58 ppm for experiments 
performed in DMSO (FWHM = 117 Hz) [70]. 
Both T1 (Figure 2F) and T2 (Figure 2G) were 
increased with increasing pH. We also observed 
increased signal intensity at higher pH using global 
single pulse spectroscopy with full relaxation (Figure 
2H). 
Compared to spectra in DMSO (FWHM = 117 
Hz) [70], we observed a broader peak for TF in serum 
(FWHM = 528 Hz) at -61 ppm (Figure 2I). In addition, 
we characterized T1 (Figure 2J) and T2 (Figure 2K) in 
human serum in order to optimize pulse sequences 
for subsequent in vivo measurements. T1 of TF in 
serum was 1017 ms (Figure 2J, R² = 0.999), which was 
comparable to the T1 of 1000 ms in DMSO (Figure 2B). 
Conversely, T2 was markedly shortened to 4 ms 
(Figure 2K, R² = 0.963) in the presence of serum, 
which is 93-fold lower than the T2 of 465 ms in DMSO 
[70]. 
We obtained a detection limit for the 19F CRP 
using 19F MRS, validating the concentrations with 
mass spectrometry. At an SNR threshold of 5, the 
LOD was 1.9 µg/g, which is equal to 5.04e + 15 19F 
atoms in a volume of 400 µL (Figure 2L). 
In vivo detection of teriflunomide in the 
abdominal region of healthy animals 
Similar to TF spectra in CMC phantoms, we 
observed a TF peak at -61 ppm in healthy Dark Agouti 
rats (n=2) using 19F MRS (Figure S1A). Qualitatively, 
we discerned an initial increase in 19F MR signal 
followed by gradual decrease during the observation 
period of 30 minutes. We also detected TF in the 
abdominal region of healthy C57BL/6 mice (Figure 
S1B) 24 hours after the last drug administration, using 
the 19F CRP. 
In vivo detection of teriflunomide in the head 
region 
Similar to CMC phantoms and in vivo 
measurements in the rat abdomen, we observed a TF 
peak at -61 ppm in the mouse head region. We 
studied changes in TF levels in TF-treated healthy 
mice (Figure 3A, n = 6 on day8, n = 5 on day14, from 1 
EAE experiment), and TF-treated EAE mice (Figure 
3B, n = 7 on day8, n = 4 on day14, from 1 EAE 





experiment). Differences in animal numbers between 
the time points were either due to technical problems 
(4 cases) or due to animal welfare (mice needed to be 
euthanized due to disease severity, 2 cases). We 
observed a distinct second 19F peak in healthy and 
EAE animals (-75 to -85 ppm). The -75 ppm peak was 
seen at a later stage of EAE and was also observed in 
the abdomen of EAE mice (data not shown). 
The 19F MR signal from the processed spectra of 
EAE and healthy mice is represented in both TD as 
FID fit (Figure 3C) and FD as peak area (integral of the 
main peak) at -61 ppm (Figure 3D) and SNR1 of this 
peak (Figure 3E). Data from these mice are shown 
separately in Table S1 (the raw data is also available 
as supplemental material). We did not observe any 
significant differences between the groups between 
day 8 and day 14, between EAE and healthy control 
mice (all p > 0.1) or in the pairwise comparisons (all 
p > 0.1) for all data, irrelevant whether FID fit, integral 
or SNR of main peak. In addition, we did not observe 
differences in variance of the 19F signal intensities (FID 
fit, integral or SNR) among the animals groups on any 
day or any of the pairwise comparisons (all p > 0.1). 
Ex vivo determination of teriflunomide levels in 
healthy and EAE animals 
The TF-derived signal was also measured in the 
serum of SJL/J EAE mice by 19F MRS (Figure S1C). TF 
concentrations in serum, CSF and perfused brain 
tissue were quantified by HPLC/MS for both SJL/J 
and C57BL/6 mice (Table 1). We calculated the LOD 
of the HPLC method to be 4.9 pg/g. In SJL/J mice 
there was a strong difference between biological 
samples (main effect p < 0.001), but no significant 
difference between healthy and EAE animals. TF 
concentrations in serum were an order of magnitude 
higher than those in perfused brain tissue or CSF, for 
both healthy and EAE animals (all p values < 0.001) 
(Figure 4A, left panel). In C57BL/6 mice, there was 
again a strong difference between biological samples 
 
Figure 2. 19F MR characterization of teriflunomide in different chemical environments. (A) 19F MR spectrum of TF in a DMSO phantom (global single pulse, TR=1000 ms, acquisition 
time = 16 s, concentration: 27.02 mg/mL in 1 mL). (B) Spectroscopic determination of T1 of teriflunomide in DMSO (T1 = 1000 ms). (C) Spectroscopic determination of T2 of 
teriflunomide in DMSO (T2 = 465 ms) using a CPMG sequence. (D) Correlation of the relaxation rates R1 and R2 (inverse T1 and inverse T2) with the concentration of the 
contrast agent gadopentetate dimeglumine (0.5, 1, 2, 4 mM) in DMSO (R = 0.998, p = 9.17e-6 for R1 and R = 0.999, p = 0.001 for R2). TF concentration = 27.02 mg/mL. (E) 19F 
MR spectrum of TF in a carboxymethylcellulose (CMC) phantom (global single pulse, TR=1000 ms, acquisition time = 16 s, concentration: 2.70 mg/mL in 1 mL). (F) Change of 
the 19F T1 with pH in CMC. (G) Change of the 19F T2 with pH in CMC. (H) Change of the 19F signal intensity with pH in CMC; concentration in CMC: 2.70 mg/mL in 1 mL, pH 
was controlled by adding HCl and NaOH. (I) 19F MR spectrum of teriflunomide in a serum phantom (acquisition time = 8 s, concentration: 1.3 mM in 1 mL). (J) Spectroscopic 
determination of T1 of teriflunomide in human serum (T1 = 1017 ms). (K) Spectroscopic determination of T2 of teriflunomide in human serum (T2 = 4 ms) using a CPMG 
sequence. (L) Assessment of the spectroscopic limit of detection (SNR1) using different TF concentrations in serum (19F MRS measured with a 19F CRP, global single pulse, 
TR = 1000 ms, acquisition time = 17 min). 
 





(main effect p < 0.001), with TF concentrations in 
serum greater than those in perfused brain tissue or 
CSF (p < 0.001). Upon post-hoc comparisons, we 
observed that TF concentrations in the CSF were 
greater than in the perfused brain tissue, both for 
C57BL/6 EAE mice (p = 0.0025) and for C57BL/6 
healthy control mice (p = 0.032) (Figure 4A, right 
panel). 
 
Table 1. Concentrations of teriflunomide in µg/g detected via 
HPLC/MS from ex vivo samples from EAE and healthy SJL/J and 
C57BL/6 mice (median ± interquartile range) 
 SJL/J  C57BL/6 
EAE (n = 7) Healthy (n = 6) EAE (n = 4) Healthy (n = 3) 
Serum 32.5 ± 13.8 33.8 ± 17.9  19.0 ± 6.8  20.6 ± 7.4  
CSF 1.7 ± 2.2  1.0 ± 1.0  0.5 ± 0.5 0.9 ± 0.3 
Brain 0.6 ± 0.9 0.5 ± 0.3 0.1 ± 0.0 0.3 ± 0.1 
 
 
We observed significant differences in the 
variance of TF concentrations. In SJL/J mice, these 
differences were seen among perfused brain, CSF and 
serum samples (p < 0.001) but not between EAE and 
healthy control groups when considering all ex vivo 
samples (p = 0.945). When comparing EAE vs. healthy 
controls for each tissue separately (pairwise 
comparisons), the variance in TF concentration was 
significantly greater in the EAE group in the case of 
brain tissue (p = 0.048), but not CSF and serum 
samples (Figure 4A, left panel). In C57BL/6 mice, 
differences in variance were also seen among 
perfused brain, CSF and serum samples (p < 0.001). 
There was again no difference in TF variance between 
EAE and healthy controls (p = 0.406), even when 
performing the pairwise comparisons for each tissue 
(Figure 4A, right panel). 
The HPLC/MS quantification of TF 
concentrations was important to establish the ground 
truth for validating in vivo 19F MRS data. A calibration 
of FD 19F MRS signal intensities with HPLC/MS 
concentration values in mouse serum (spiked with 
different TF dilution) is shown in Figure 4B. The 
resulting linear fit (Spearman ρ = 1.000, p = 0.333), 
was used to estimate the concentration from the FD 
19F MR signal intensity. Compared to the HPLC/MS 
quantification, TF concentrations estimated from 19F 
MRS were elevated with a maximum relative 
deviation of 130% and a mean relative deviation of 
83% (Figure 4C). However, TF concentrations 
determined by 19F MRS showed a clear correlation 
with concentrations determined by HPLC/MS 
(Spearman ρ = 0.903, p = 0.001). 
 
 
Figure 3. 19F MR detection of teriflunomide (TF) in vivo. (A-B) 19F MR teriflunomide signal from the heads of healthy (A) and EAE (B) mice on day 8 and day 14 following the start 
of daily teriflunomide treatments. Measurements were performed 16-24 h after the last gavage (acquisition time = 17 min). (C-D) 19F MR signal calculated in the time domain as 
signal intensity from the FID fit (C) and frequency domain as peak area, integral of the main peak (δF = -61ppm) using the Lorentzian fit (D) and SNR (signal per one SD of the 
noise) of the same peak (E) plotted as arbitrary units for all EAE and healthy SJL/J animals for days 8 and 14. 






Figure 4. Detection of teriflunomide by mass spectrometry. (A) Plot showing the detection of teriflunomide by mass spectrometry in the brain, CSF and serum of EAE and healthy 
animals of both strains SJL/J and C57BL/6 on day 14 (EAE SJL/J n = 7, healthy SJL/J n = 6, EAE C57BL/6 n = 4, healthy C57BL/6 n = 3). (B) Calibration curve for 19F MRS 
quantification using HPLC/MS concentrations of TF dissolved in serum and the corresponding 19F MRS signal intensities (SNR1; 19F MRS measured with a 19F CRP, global single 
pulse, TR = 1000 ms, acquisition time = 17 min, linear fit with Spearman ρ = 1.000, p = 0.333). (C) Correlation of 19F MR signal quantification ex vivo in the serum of TF treated 
mice with concentrations measured by mass spectrometry in serum (19F MRS measured with a 19F CRP, global single pulse, TR = 1000 ms, acquisition time=1 min, Spearman 
ρ = 0.903, p = 0.001, dotted line with slope = 1). 
 
Discussion 
In this study, we show that non-invasive 19F MR 
methods can be used to detect TF in vivo. Ex vivo 
HPLC/MS analyses confirmed the availability of TF 
in the CNS at pharmacologically relevant 
concentrations [56]. The therapeutic effect was 
strain-dependent, being less pronounced in C57BL/6 
mice. This could be attributed to the diverging 
pathology that both strains present during the course 
of an EAE: in SJL/J mice the pathology is mainly 
localized to the brain, in C57BL/6 mice lesions are 
mostly prevalent in the spinal cord [71]. EAE in SJL/J 
mice presents as a relapsing-remitting disease (similar 
to RRMS patients). EAE in C57BL/6 mice follows a 
chronic disease progression without remissions and 
relapses (similar to progressive/secondary 
progressive MS). These strain differences were behind 
the rationale for studying different mechanism of 
action of DMDs for the treatment of RRMS and 
P/SPMS [56]. Different responses to TF treatment 
among species and strains could be also attributed to 
differences in target binding potencies [72] or immune 
cell susceptibilities [56]. 
Despite increasing concerns regarding the risks 
of long-term deposition in the brain, contrast- 
enhanced MRI remains a key tool for diagnosis and 
differential diagnosis [73-75]. In this study we 
observed contrast-enhanced brain lesions at the 
expected time of peak disease, even in asymptomatic 
TF-treated EAE mice. This underscores the critical 
role of MRI for early detection of pathology in MS and 
EAE, even prior to the occurrence of clinical signs and 
that clinical scoring alone is not sufficient to fully 
assess the disease status [58]. 
In addition to peripheral effects and mechanisms 
of action, many DMDs for MS are expected to work 
within the CNS. Thus a non-invasive method that 
studies drug distribution in the CNS would be a 
useful tool in MS drug development and in treatment 
monitoring. Hence, we are addressing an area of 
major interest in MS that could benefit from new 
studies investigating therapies and their distribution 
in vivo. Nevertheless, the in vivo detection of 19F 
compounds with 19F MR methods remains 
challenging. This is primarily due to the low drug 
concentrations available in the human body [70]. 
Additionally, technological challenges in terms of 
hardware sensitivity and measurement precision and 
accuracy limit swift transitions to clinical applications. 
19F MR spectroscopy techniques have been used 
for several years to detect fluorinated drugs in small 
animals [33-38] and humans [39-45]. The chemo-
therapeutic agent 5-Fluorouracil (5-FU) has been 
studied by 19F MRS in tumor-bearing rats [34] and 
patients with head and neck tumors [45] and more 
recently it was detected by 19F MRI in tumor bearing 
mice using high drug doses and fast spin echo 





sequences [38]. 19F MRS imaging (MRSI) of 
fluvoxamine and fluoxetine was performed in 
patients with major depressive disorder who were on 
long term treatment with these drugs [42]. 
Alternatively, therapeutic compounds containing 
cytosine (e.g. the neuroprotective drug citicoline or 
the anticancer drug gemcitabine) can be detected via 
chemical exchange saturation transfer (CEST) MRI; 
these molecules contain exchangeable protons that 
can be selectively saturated and then detected 
indirectly through the water signal. Recently, the 
potential of CEST MRI to detect these therapeutic 
compounds in vivo has been shown [76, 77]. 
Compared to studies investigating fluorinated 
drugs at high doses [38, 44], in our present study we 
administered therapeutic doses of the fluorinated 
drug, which previously had shown an influence on 
the disease course in SJL/J EAE mice [56]. 
Additionally, we did not only acquire 19F MR signals 
right after administration of the drug as has 
previously been done [36, 78, 79], but we also detected 
accumulated TF levels over time, and during 
pathology. 
Furthermore, in this study we characterized the 
MR properties of TF in serum, DMSO and CMC and 
at varying pH, to assess alterations in the 
physicochemical and MR properties, which are 
important to consider during interpretation of data. 
The pH in different compartments has a known 
impact on the solubility, binding kinetics and hence 
bioavailability of drug molecules [80]. pH variations 
result in different protonation of molecules, changing 
their MR properties, such as chemical shift [81] and 
relaxation times [82-86]. pH changes can also effect 
drug solubility, e.g. at low pH only a fraction of TF is 
dissolved and thus detected by 19F MR, the 
precipitated portion will not contribute to the MR 
signal. Furthermore, pH could also affect the 
properties of the CMC support matrix. The stomach 
environment could alter its protonation state and 
therefore its solubility, thereby affecting the 19F MR 
properties of TF [87, 88]. 
While the T1 of TF in serum was comparable to 
that in DMSO, the T2 was substantially shortened in 
serum, which is also indicated by a broader TF peak 
[89] in serum, when compared to DMSO. Similar to 
micelles and nanoparticles [90], CMC could perhaps 
bind to serum proteins, although one would assume 
that the drug will be mostly bound to serum proteins 
in the blood stream. In any case, a shortening of T2 if 
caused by drug serum binding (or CMC serum 
binding) makes signal detection more challenging 
when using standard pulse sequences. 
Here, we used a three-parameter exponential fit, 
taking an offset of the signal decay into account until 
reaching the level of noise. Potentially, another 
fraction of TF exhibiting a different relaxation 
behavior might contribute to the acquired signal, 
which however, cannot be distinguished in the 
experiments performed here. Conversely, an increase 
in TF MR signal can be expected in short TR 
measurements in the presence of gadolinium-based 
contrast agents due to a reduction in T1 saturation 
effects. This has implications for neuroinflammation 
since TF is likely to localize at sites of inflammatory 
activity in the brain or the spinal cord, and thus its 
proximity to gadolinium-enhanced lesions in the CNS 
might increase its detection. 
We previously showed that temperature can 
influence the MR parameters of TF [70]. Here, 19F MR 
signals increased with increasing pH. Differences in 
spectral widths between TF in DMSO, CMC and 
serum can be explained by environmental effects such 
as different solubility of the drug in the medium and 
protein-binding effects (99% of TF is plasma protein 
bound) [91]. 
As a first step towards studying drug 
distribution in vivo, we measured the 19F MR signal in 
the abdominal region of healthy rats. The 19F MR 
signal was acquired directly after TF administration 
into the stomach; we assume that most of this signal 
originates from the stomach during the first few 
minutes. Changes in 19F signal in rats following oral 
administration can be attributed to pH and 
temperature changes in the stomach that may alter the 
solubility or binding of TF to CMC. We hypothesize 
that pH might play an ambivalent role in different 
environments e.g. in the stomach, in CMC or in 
DMSO with respect to solubility and consequently TF 
detection. The decreasing trend in 19F signal after the 
six-minute measurement could suggest a gradual 
influence of the acidic pH in the stomach on signal 
intensity but also a gradual distribution to the 
intestinal compartment and absorption into the blood 
circulation. We expect that the 19F MR signal from the 
abdominal region in EAE mice, measured 24 h after 
the last drug administration originates primarily from 
the liver (highest concentration of TF after blood) [92]. 
When studying the in vivo 19F MR signal of TF in 
the head region, we observed no changes between 
day 8 and day 14 p.i. In patients, TF has a half-life of 
approximately 15 days [51, 93] administered at a dose 
of 14 mg per day (circa 250 µg/kg). This corresponds 
to a mouse dose of circa 3 mg/kg [60]. In the current 
study and previous ones [55, 56] mice received 3-10 
times this dose, which is needed to have an effect on 
the disease course [56]. Leflunomide, the prodrug of 
TF, reaches steady state in 7 weeks when 
administered orally at a daily dose of 20 mg (circa 
350 µg/kg). If linear pharmacokinetics are assumed 





[94], the steady state of TF dose used in mice is 
expected to be reached earlier than day 8. 
Interestingly, we observed a second peak in the 
range of -75 to -85 ppm alongside the main TF peak 
at -61 ppm in healthy and EAE mice, and in their ex 
vivo sera, but not in in vivo experiments carried out 
soon after drug administration in the rat. We assume 
that this peak is a TF metabolite. While we are not 
aware of any specific TF metabolites that resonate at 
this range, we are certain that this is not a 
contamination since it was not reproduced in our 
phantom experiments and our animals had not been 
exposed to any other 19F compounds. We believe this 
second peak surely warrants further investigation and 
might be valuable to further pharmacological 
research. 
The major metabolite of TF in human plasma is 
4-trifluoro-methylaniline oxanilic acid (4-TMOA) [51, 
95]. This metabolite has a chemical shift of -59.7 ppm 
and would overlap with the TF parent compound 
[96]. Other metabolites such as mono-oxidated TF 
sulfate, 4-trifluoromethylaniline 2-hydroxy- 
maionanlc malonamic acid and its sulfate were 
identified in urine, and mono-oxidated TF sulfate and 
mono-oxidated TF in feces [95]. 
The chemical shifts of most CF3 groups lie 
within the range of -60 to -80 ppm. A more negative 
chemical shift would indicate increased shielding of 
the CF3 group, which can occur as a result of 
branching near the CF3 group or close proximity to 
hydrogen bond donors [97]. In human subjects the 
total amount of these metabolites in plasma is lower 
than 1 % of the parent compound (in contrast to urine 
and feces) and probably not detectable in vivo [95, 98]. 
However, this might also be different in mice. 
Different metabolic rates and processes can be an 
explanation of this finding. Even the EAE pathology 
might have an impact due to changes in metabolic 
processes during inflammation [99] and warrants 
further investigation in future studies. 
In a rat EAE model, TF distribution to the brain 
was shown by whole-body autoradiography [92], 
whereas no TF could be detected in the brains of EAE 
mice when using MALDI-MS [100]. The in vivo 19F MR 
signal that we acquired in the head region of healthy 
and EAE mice with 19F MRS could reflect TF signals in 
the blood, CSF, brain parenchyma, or perhaps even 
infiltrating immune cells that are causing the 
pathology. Since we did not observe any significant 
differences in TF signal between the healthy controls 
and EAE mice in vivo, there is no evidence of 
pathology-related alterations in the drug distribution 
into the head region. 
The results from mass spectrometry 
measurements also did not show significant 
differences in TF concentrations in perfused brain 
tissue, CSF and serum between EAE mice and healthy 
controls. Nevertheless, TF was detectable in CSF and 
perfused brain tissue in both SJL/J and C57BL/6 
mice, though these were significantly lower than 
serum concentrations. This distribution pattern could 
reflect the route of the drug from the systemic 
circulation to the brain via the CSF or the vasculature.  
The observed interindividual differences in TF 
levels are consistent with a TF study performed in 
patients where steady state plasma concentrations 
were in the range 7.6-14.8 mg/L and 11-16.9 mg/L 
following at least 8 weeks daily intake [93]. 
One caveat of the study was that we could not 
perform automatic power adjustments during the in 
vivo measurements in the mouse head, due to low 
SNR; instead we performed short measurements with 
different reference power settings on the living animal 
to determine the optimal reference power to reach the 
90 ° flip angle. Nonetheless the uncertainty in the flip 
angle due to potential differences in the positioning of 
the animal or coil filling factors could be a potential 
source of variability in the 19F detection. We did not 
use a reference tube during the in vivo measurements 
for several technical (overlapping signals, potential 
signal losses), physical (complex in vivo setup and 
limited space) and animal welfare related (breathing 
obstruction) reasons. 
A comparison between the 19F MRS method and 
the HPLC/MS method in ex vivo serum samples 
showed a linear correlation. However, there were 
deviations between HPLC/MS and 19F MRS 
concentration estimations; one could attribute these 
either to an overestimation by the 19F MRS method or 
an underestimation by the HPLC/MS method. The 
proportion of metabolite to parent compound might 
be higher in mice than in human subjects. Therefore, 
one could speculate, that the 19F MRS peak at -61 ppm 
overlaps with a significant amount of its metabolite. 
Potentially, metabolites detected by 19F MRS are not 
quantified by the HPLC/MS method and thereby 
could explain the deviation in the concentration 
estimation in both methods. Alternatively, differences 
in the properties of TF between spiked and ex vivo 
serum samples (e.g. differences in protein 
composition, conductive properties) might be a 
source for this deviation. Still, both methods were 
shown to correlate with each other and indicate that 
TF concentrations could be measured with 19F MRS in 
future studies, possibly even as non-invasive tool in 
vivo. 
While there are still limitations in terms of 
technological development — in particular with 
regard to exact calibration of reference power due to 
low 19F amounts — we highlight here the usefulness 





and general feasibility of this approach for studying 
the biodistribution of fluorinated drugs. In this study, 
we needed to address several challenges for detecting 
TF in vivo. The quadrature, cryogenically cooled 
surface coil that we used in this study confers a 
theoretical increase in sensitivity of 40% [101] 
compared to a linear coil, but prohibits a dual-tunable 
feature that accommodates 1H imaging. 
To distinguish the distribution of TF in different 
brain regions 19F MR imaging or localized 19F MR 
spectroscopy would be highly valuable. This is 
possible when studying neuroinflammation with 19F 
MRI and perfluoro-15-crown-5-ether nanoparticles; 
the 19F MR signal in the CNS and associated 
lymphatic system is sufficient for single-voxel 
spectroscopy e.g. PRESS (Point RESolved 
Spectroscopy) [61] and 19F MR imaging, even when 
using a RT coil [61]. This is not the case for small 
molecules such as TF that are available in much 
smaller quantities in the CNS. Understanding the 
specific 19F MR properties of the drug of interest will 
allow the choice and tailoring of appropriate MR 
pulse sequences. While determining the specific 
origin of signals detected with non-localized MR 
spectroscopy is not possible, hypotheses on the origin 
of signals could be verified by using single voxel 
spectroscopy. Nevertheless, due to a low T2 of TF in 
serum as well as the low TF concentrations expected 
in vivo at a therapeutic level, localized single-voxel 
MR spectroscopy or MRSI are not trivial techniques to 
be applied. 
In this study we characterized the MS drug 
teriflunomide in phantom experiments and in vivo in 
the animal model of MS. The 19F CRP significantly 
boosts SNR compared to other available RF coil 
technologies and enabled the in vivo detection of 
TF-derived 19F MR signals in EAE mice within a short 
time [62]. However, more technological developments 
are needed to further boost 19F MR signal sensitivity 
to ultimately achieve drug quantification within 
specific tissue compartments [102]. The combination 
of multiple approaches such as using cryogenically 
cooled RF coils [62], higher magnetic fields [103] and 
methods to accelerate data acquisition such as 
compressed sensing [104] will be key to achieve this 
goal and allow monitoring drugs in vivo with 19F MRI. 
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